Post-spinoff strategy unveiled in CEO Kim Kyung-ah’s first press conference

SAN FRANCISCO – Samsung Epis Holdings, the holding company of biosimilar drug developer Samsung Bioepis Co., has pledged to put more effort into developing new drugs while bolstering its biosimilar sector, aiming to advance at least one new drug candidate into clinical trials each year.

“At Samsung Bioepis, we have been strengthening our research, clinical medicine, process, and development capabilities to a global level through the development of biosimilars,” said Kim Kyung-ah, who heads both Samsung Epis Holdings and Samsung Bioe

📰

Continue Reading on The Korea Herald

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →